IP Library Granted Patent US 50,724
Granted Patent E1
US 50,724 · App. 18/112,640 · Granted Jan 6, 2026

4-membered ring carboxamides used as nematicides

Inventors: Anthony Cornelius O'Sullivan (Stein, CH); Regis Jean Georges Mondiere (Stein, CH); Olivier Loiseleur (Stein, CH); Tomas Smejkal (Stein, CH); Torsten Luksch (Stein, CH); Andre Jeanguenat (Stein, CH); Raphael Dumeunier (Stein, CH); Edouard Godineau (Stein, CH); Thomas Pitterna (Stein, CH)
Assignee: SYNGENTA CROP PROTECTION AG
A01N37/18A01N37/34A01N37/40A01N43/20A01N43/40C07C211/37C07C233/14C07C233/23C07C233/32C07C233/66C07C233/81C07C233/90C07C235/54C07C235/62C07C251/44C07C255/57C07C265/10C07C291/10C07C317/32C07C323/62C07D213/81C07D213/82C07D231/14C07D239/28C07D263/52C07D305/08C07B2200/07C07C2601/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 50,724
App. No.
18/112,640
Granted
Jan 6, 2026
Kind
E1
Abstract

Compounds of the formula (I), in which the substituents are as defined in claim 1 , are suitable for use as nematicides.

Claims (32)

1 . A compound selected from

2 . A composition, comprising: a compound of formula (I) selected from

wherein the ratio of the compound of formula (I) to its enantiomer is greater than 1.5:1, greater than 2.5:1, greater than 4:1, greater than 9:1, or greater than 20:1.

3 . A The compound according to claim 1 which is, wherein the compound is

4 . A The compound according to claim 1 which is, wherein the compound is

5 . A The compound according to claim 1 which is, wherein the compound is

6 . A The compound according to claim 1 which is, wherein the compound is

7 . A The composition according to claim 2 comprising a compound of formula, wherein the compound of formula (I) is

wherein the ratio of the compound of formula (I) to its enantiomer is greater than 1.5:1, greater than 2.5:1, greater than 4:1, greater than 9:1, or greater than 20:1.

8 . A The composition according to claim 2 comprising a compound of formula, wherein the compound of formula (I) is

wherein the ratio of the compound of formula (I) to its enantiomer is greater than 1.5:1, greater than 2.5:1, greater than 4:1, greater than 9:1, or greater than 20:1.

9 . A The composition according to claim 2 comprising a compound of formula, wherein the compound of formula (I) is

wherein the ratio of the compound of formula (I) to its enantiomer is greater than 1.5:1, greater than 2.5:1, greater than 4:1, greater than 9:1, or greater than 20:1.

10 . A The composition according to claim 2 comprising a compound of formula, wherein the compound of formula (I) is

wherein the ratio of the compound of formula (I) to its enantiomer is greater than 1.5:1, greater than 2.5:1, greater than 4:1, greater than 9:1, or greater than 20:1.

11 . A composition according to claim 2 comprising a compound of formula

wherein the ratio of the compound of formula (I) to its enantiomer is greater than 1.5:1, greater than 2.5:1, greater than 4:1, greater than 9:1, or greater than 20:1.

12 . The composition according to claim 2 , wherein the ratio of the compound of formula (I) to its enantiomer is greater than 9:1.

13 . A method of controlling pests in soil, the method comprising: applying to the soil a composition according to claim 12 .

14 . The method of claim 13 , wherein the application to the soil is through a solid carrier treated with the composition.

15 . The method of claim 14 , wherein the solid carrier is a seed.

16 . The method of claim 13 , wherein the pest is a nematode.

17 . The composition of according to claim 2 , wherein the ratio of the compound of formula (I) to its enantiomer is greater than 20:1.

18. The composition according to claim 8 , wherein the ratio of the compound of formula (I) to its enantiomer is greater than 2.5:1.

19. The composition according to claim 8 , wherein the ratio of the compound of formula (I) to its enantiomer is greater than 4:1.

20. The composition according to claim 8 , wherein the ratio of the compound of formula (I) to its enantiomer is greater than 9:1.

21. The composition according to claim 8 , wherein the ratio of the compound of formula (I) to its enantiomer is greater than 20:1.

22. The composition according to claim 8 , wherein the composition is free of the enantiomer of the compound of formula (I).

23. The composition according to claim 19 , further comprising a second compound that is a biological active agent.

24. The composition of claim 23 , the second compound is selected from an acaricide, an algicide, a bactericide, a biological agent, an insect repellant, a nematicide, a mollusicide, or a fungicide.

25. The composition of claim 23 , wherein the second compound is selected from azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imazalil, imibenconazole, ipconazole, metconazole, myclobutanil, pefurazoate, penconazole, prothioconazole, pyrifenox, prochloraz, propiconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triflumizole, triticonazole, ancymidol, fenarimol, nuarimol, bupirimate, dimethirimol, ethirimol, dodemorph, fenpropidine, fenpropimorph, spiroxamine, tridemorph, cyprodinil, mepanipyrim, pyrimethanil, fenpiclonil, fludioxonil, benalaxyl, furalaxyl, metalaxyl, R-metalaxyl, ofurace, oxadixyl, benomyl, carbendazim, debacarb, fuberidazole, thiabendazole, chlozolinate, dichlozoline, iprodione, myclozoline, procymidone, vinclozoline, boscalid, carboxin, fenfuram, flutolanil, mepronil, oxycarboxin, penthiopyrad, thifluzamide, guazatine, dodine, iminoctadine, azoxystrobin, dimoxystrobin, enestroburin, fluoxastrobin, kresoxim-methyl, metominostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin, ferbam, mancozeb, maneb, metiram, propineb, thiram, zineb, ziram, captafo, captan, dichlofluanid, fluoroimide, folpet, tolylfluanid, bordeaux mixture, copperhydroxid, copperoxychlorid, coppersulfat, copperoxid, mancopper, oxine-copper, dinocap, nitrothal-isopropyl, edifenphos, iprobenphos, isoprothiolane, phosdiphen, pyrazophos, tolclofosmethyl, acibenzolar-S-methyl, anilazine, benthiavalicarb, blasticidin-S, chinomethionat, chloroneb, chlorothalonil, cyflufenamid, cymoxanil, dichlone, diclocymet, diclomezine, dicloran, diethofencarb, dimethomorph, SYP-L190 (Flumorph), dithianon, ethaboxam, etridiazole, famoxadone, fenamidone, fenoxanil, fentin, ferimzone, fluazinam, fluopicolide, flusulfamide, fenhexamid, fosetyl-aluminium, hymexazol, iprovalicarb, IKF-916 (Cyazofamid), kasugamycin, methasulfocarb, metrafenone, pencycuron, phthalide, polyoxins, probenazole, propamocarb, proquinazid, pyroquilon, quinoxyfen, quintozene, sulphur, tiadinil, triazoxide, tricyclazole, triforine, validamycin, zoxamide (RH7281), mandipropamid, isopyrazam, sedaxane, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid [2-(2,4-dichlorophenyl)-2-methoxy-1-methyl-ethyl]-amide, 1-[4-[4-[(5S)5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]piperidin-1-yl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, 1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]piperidin-1-yl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone, and 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3′,4′,5′-trifluorobiphenyl-2-yl)-amide.

26. The composition of claim 23 , wherein the second compound is selected from metalaxyl, fluopyram, tioxazafen or 1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl]piperidin-1-yl]-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2026
From: O'SULLIVAN, ANTHONY CORNELIUS; MONDIERE, REGIS JEAN GEORGES; LOISELEUR, OLIVER; SMEJKAL, TOMAS; LUKSCH, TORSTEN; JEANGUENAT, ANDRÉ; DUMEUNIER, RAPHAEL; GODINEAU, EDOUARD; PITTERNA, THOMAS
To: SYNGENTA PARTICIPATIONS AG
Reel/Frame 073670/0551 →
MERGER AND CHANGE OF NAME Recorded Feb 3, 2026
From: SYNGENTA PARTICIPATIONS AG; SYNGENTA PARTICIPATIONS AG
To: SYNGENTA CROP PROTECTION AG
Reel/Frame 073670/0971 →
MERGER Recorded Jul 29, 2024
From: SYNGENTA PARTICIPATIONS AG
To: SYNGENTA CROP PROTECTION AG
Reel/Frame 068114/0282 →
Priority Claims (2)
EP 13175632 · Jul 8, 2013 · regional
EP 13175940 · Jul 10, 2013 · regional
Continuity (1)
Reissue 14903169 · Jul 1, 2014
References Cited (18)
US 11053201B2 · Hone · 2021 [cited by examiner]
US 20040014842A1 · Takeda et al. · 2004 [cited by applicant]
US 20130143811A1 · Murray et al. · 2013 [cited by applicant]
CN 1069882A · 1993 [cited by applicant]
CN 104203916A · 2014 [cited by applicant]
CN 105377036A · 2016 [cited by applicant]
WO 1993003022A1 · 1999 [cited by applicant]
WO 2004014842A1 · 2004 [cited by applicant]
WO 2006122955A1 · 2006 [cited by applicant]
WO 2013064460A1 · 2013 [cited by applicant]
WO 2014177487A1 · 2014 [cited by applicant]
WO WO2015003951A1 · 2015 [cited by examiner]
WO 2013143811A1 · 2015 [cited by applicant]
International Search Report & Written Opinion for PCT/EP2014/063895, mailed Sep. 4, 2014. [cited by applicant]
Nichols, David et al., “Synthesis and Evaluation of Substituted 2-Phenylcyclobutylamines as Analogues of Hallucinogenic Phenet hylamines: Lack of LSD-like Biological Activity”, Journal of Medical Chemistry, American Che… [cited by applicant]
Beard, Colin et al., “2-Phenlcyclobutylamine”, The Journal of Organic Chemistry, vol. 26, No. 7, Jul. 1, 1961, (Jul. 1, 1961), pp. 2335-2339, XP55136566. ISSN: 0022-3263. DOI: 10.1021jjo01351a045. [cited by applicant]
Komiskey, H. L. et al., “Inhibition of Synaptosomal Uptake of Norepinephrine and dopamine by conformationlly restricted sympathomimetic amines” in European Journal of Pharmacology, vol. 52, No. 1, pp. 37-45. (1978). [cited by applicant]
International Search Report & Written Opinion for PCT/EP2014/063895, dated Sep. 4, 2014. [cited by applicant]